PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2022
Exchange: NASDAQ
Website: https://www.pepgen.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/9/2025 | $6.00 | Buy | Guggenheim |
| 12/16/2024 | $3.00 | Neutral → Underperform | BofA Securities |
| 7/31/2024 | $12.00 | Buy → Neutral | BofA Securities |
| 12/21/2022 | $26.00 | Buy | H.C. Wainwright |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Guggenheim initiated coverage of PepGen with a rating of Buy and set a new price target of $6.00
BofA Securities downgraded PepGen from Neutral to Underperform and set a new price target of $3.00
BofA Securities downgraded PepGen from Buy to Neutral and set a new price target of $12.00
H.C. Wainwright initiated coverage of PepGen with a rating of Buy and set a new price target of $26.00
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - PepGen Inc. (0001835597) (Issuer)
4 - PepGen Inc. (0001835597) (Issuer)
4 - PepGen Inc. (0001835597) (Issuer)
4 - PepGen Inc. (0001835597) (Issuer)
4 - PepGen Inc. (0001835597) (Issuer)
4 - PepGen Inc. (0001835597) (Issuer)
4 - PepGen Inc. (0001835597) (Issuer)
4 - PepGen Inc. (0001835597) (Issuer)
4 - PepGen Inc. (0001835597) (Issuer)
4 - PepGen Inc. (0001835597) (Issuer)
SCHEDULE 13G - PepGen Inc. (0001835597) (Subject)
8-K - PepGen Inc. (0001835597) (Filer)
SCHEDULE 13D/A - PepGen Inc. (0001835597) (Subject)
8-K - PepGen Inc. (0001835597) (Filer)
424B5 - PepGen Inc. (0001835597) (Filer)
424B5 - PepGen Inc. (0001835597) (Filer)
8-K - PepGen Inc. (0001835597) (Filer)
SCHEDULE 13G/A - PepGen Inc. (0001835597) (Subject)
8-K - PepGen Inc. (0001835597) (Filer)
10-Q - PepGen Inc. (0001835597) (Filer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - PepGen Inc. (0001835597) (Issuer)
4 - PepGen Inc. (0001835597) (Issuer)
4 - PepGen Inc. (0001835597) (Issuer)
4 - PepGen Inc. (0001835597) (Issuer)
4 - PepGen Inc. (0001835597) (Issuer)
4/A - PepGen Inc. (0001835597) (Issuer)
4 - PepGen Inc. (0001835597) (Issuer)
4 - PepGen Inc. (0001835597) (Issuer)
Fastest customizable press release news feed in the world
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that management will participate in the following upcoming investor conferences: Guggenheim Securities 2nd Annual Healthcare Innovation Conference (Boston, MA) Monday, November 10, 2025 at 11:30 a.m. ET, Fireside Chat Stifel 2025 Healthcare Conference (New York, NY) Thursday, November 13, 2025 at 4:00 p.m. ET, Fireside Chat A webcast of each conference presentation will be available on the "Events & Presentations" page within the Investors
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the Company's data will be presented in two oral presentations at the 30th Annual International Congress of the World Muscle Society (WMS) being held October 7-12, 2025, in Vienna, Austria. One of the presentations will include previously reported positive FREEDOM-DM1 Phase 1 clinical data. Title: Results from 15 mg/kg single dose PGN-EDODM1 cohort of FREEDOM-DM1- a phase 1 study in people with myotonic dystrophy type 1 (DM1) (#230) Session: Clinical T
PepGen Inc. (NASDAQ: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the closing of its previously announced underwritten public offering of 35,937,500 shares of its common stock, which includes the exercise in full of the underwriters' option to purchase 4,687,500 additional shares, at the public offering price of $3.20 per share. The aggregate gross proceeds to PepGen from this offering, before deducting underwriting discounts and commissions and offering expenses, were $115 million. Leerink Partners and Stifel acted as
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the pricing of an underwritten offering of 31,250,000 shares of its common stock at a price to the public of $3.20 per share. The aggregate gross proceeds to PepGen from this offering are expected to be $100 million, before deducting underwriting discounts and commissions and offering expenses payable by PepGen. The offering is expected to close on or about September 26, 2025, subject to customary closing conditions. In addition, PepGen has granted the under
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that it has commenced an underwritten public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares and pre-funded warrants are being offered by PepGen. In addition, PepGen intends to grant the underwriters a 30-day option to purchase additional shares of its common stock. The proposed offering is subject to market and other conditions, and there can be no
– 53.7% mean splicing correction observed following a single 15 mg/kg dose of PGN-EDODM1, with all patients showing an improvement in splicing – – PGN-EDODM1 was generally well-tolerated at 15 mg/kg, with drug-related adverse events mild or moderate in severity – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, announced positive clinical data today from the 15 mg/kg dose cohort of its ongoing FREEDOM-DM1 Phase 1 single ascending dose (SAD) study in patients with myotonic dystrophy type 1 (DM1). These latest results d
– Last patient dosed in 15 mg/kg cohort of FREEDOM-DM1; on track to report topline data from study in early Q4 2025 – – FREEDOM to conclude with the 15 mg/kg cohort based on splicing and safety data observed to date; clinical sites will begin transitioning to the Phase 2 multiple ascending dose study, FREEDOM2-DM1 – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended June 30, 2025. "This quarter, we made further progress in the develo
– PGN-EDO51 did not achieve target dystrophin levels in CONNECT1-EDO51 trial; Company to discontinue development of DMD programs – – PGN-EDO51 at 10 mg/kg was generally well tolerated; all treatment-related adverse events were mild – – DM1 program on track to read out FREEDOM-DM1 15 mg/kg cohort in second half of 2025 and FREEDOM2-DM1 5 mg/kg cohort in Q1 2026 – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies, today announced that based on the levels of dystrophin protein measured in the 10 mg/kg cohort of its CONNECT1-EDO51 study investigating PGN-EDO51 in Duchenne muscular dystrophy (DMD) patients amenable
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Kasra Kasraian, PhD, as Chief Technology Officer (CTO). Dr. Kasraian brings over 25 years of experience in product and process development, CMC strategy, and technical operations, spanning small and large molecules, as well as cell and gene therapies. "We are pleased to welcome Kasra to our executive leadership team," said James McArthur, PhD, President and Chief Executive Officer of PepGen. "He brings a rare depth of expertise in product
– Reported positive DM1 patient data with mean splicing correction of 29.1% following a single dose of PGN-EDODM1 at 10 mg/kg – – FREEDOM-DM1 data from 15 mg/kg cohort expected in the second half of 2025 – – CONNECT1-EDO51 data from 10 mg/kg cohort expected in the third quarter of 2025 – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended March 31, 2025. "Our EDO platform's unique ability to efficiently deliver oligonucleotides into the
Live finance-specific insights
– Significant mean splicing correction of 29.1% following a single dose of PGN-EDODM1 at 10 mg/kg – – PGN-EDODM1 observed to have favorable emerging safety profile – – Conference call scheduled today at 8:00 a.m. ET – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced initial positive clinical data from the 5 and 10 mg/kg dose cohorts in the ongoing FREEDOM-DM1 Phase 1 trial investigating PGN-EDODM1 in myotonic dystrophy type 1 (DM1). "These results far exceeded our expectations for splicing correctio
– PGN-EDO51 at 5 mg/kg was well tolerated, and all patients continued to long-term extension portion of trial. Dosing of second cohort at 10 mg/kg is ongoing – – Four doses of PGN-EDO51 at 5 mg/kg achieved mean exon skipping levels of 2.15% after three months of dosing – – PGN-EDO51 at 5 mg/kg showed mean muscle-adjusted dystrophin level of 1.49%, a 0.70% increase from baseline, after three months of dosing – – PGN-EDO51 at 5 mg/kg showed mean absolute dystrophin level of 0.61%, a 0.26% increase from baseline, after three months of dosing – – Conference call scheduled for 4:30 p.m. ET – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation
BOSTON, March 16, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, will report its fourth quarter and full year 2022 financial results and provide a corporate update on Thursday, March 23, 2023. PepGen's management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30pm ET. The event will be webcast live under the Events & Presentations section of the Investor Relations section of PepGen's website. A replay of the event will be archived
- PGN-EDO51 exhibited the highest levels of oligonucleotide delivery and exon skipping in a clinical study following a single dose when compared to publicly available clinical data for other exon 51 skipping approaches - - PGN-EDO51 was generally well-tolerated - - PepGen plans to initiate a Phase 2a multiple ascending dose (MAD) clinical trial in Duchenne muscular dystrophy (DMD) patients in 1H 2023 - - Data supports the potential of PepGen's Enhanced Delivery Oligonucleotide (EDO) platform in neuromuscular diseases - - Company to host conference call today at 8:00 a.m. ET to discuss these results - BOSTON, Sept. 28, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (NASDAQ:PEPG), a clinical-sta
Live Leadership Updates
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Kasra Kasraian, PhD, as Chief Technology Officer (CTO). Dr. Kasraian brings over 25 years of experience in product and process development, CMC strategy, and technical operations, spanning small and large molecules, as well as cell and gene therapies. "We are pleased to welcome Kasra to our executive leadership team," said James McArthur, PhD, President and Chief Executive Officer of PepGen. "He brings a rare depth of expertise in product
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointments of Lisa Wyman and Mitchell H. Finer, PhD, to its Board of Directors. Ms. Wyman and Dr. Finer are industry veterans, each bringing decades of executive experience in the life sciences to the Company. "We are thrilled to welcome Lisa and Mitch to our Board of Directors," said James McArthur, PhD, President and CEO of PepGen. "Lisa's proven ability to scale manufacturing for mid- to late-stage clinical trials and guide clinical-stage companies
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development (R&D), effective immediately. Dr. Streck will join the PepGen Executive Team and will be responsible for leading the R&D organization. "We are very pleased that Paul is joining PepGen at such an important time for the Company," said James McArthur, Ph.D., President and CEO of PepGen. "Throughout his career, Paul has served in leadership roles across both l
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the expansion of its executive team with the appointments of Afsaneh Mohebbi, Ph.D., as Senior Vice President, Portfolio and Program Management and Dave Borah, CFA, as Senior Vice President, Investor Relations and Corporate Communications, effective immediately. "We are thrilled to welcome Afsaneh and Dave to PepGen. The addition of these two senior team members will enhance our expertise in critical areas of the organization, and we eagerly anticipate thei
BOSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the expansion of its executive team with the appointment of Mary Beth DeLena as General Counsel and Secretary. Ms. DeLena joins PepGen with over 20 years of experience advising global life science companies in a broad range of strategic, transactional, and corporate matters with extensive experience in business development, finance, securities, corporate governance, employment and commercial law. Prior to PepGen, Ma
BOSTON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Howard Mayer, M.D. to the PepGen Board of Directors, effective November 15, 2023. "We are pleased to welcome Dr. Mayer to the PepGen Board," said James McArthur, Ph.D., President and CEO of PepGen. "His extensive clinical development and regulatory experience across a variety of therapeutic areas, including multiple global regulatory filings and approvals in rare diseases, will be invaluable to Pe
BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. ("PepGen"), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Habib Joseph Dable to its Board of Directors. Mr. Dable is the former President and Chief Executive Officer of Acceleron Pharma, and brings nearly three decades of experience working with emerging biotech and big pharma companies. "Habib joins the Board at a pivotal time for PepGen, as we continue to execute our clinical development strategy for PGN-EDO51, our lead candidate in Duchenne muscular dys
This live feed shows all institutional transactions in real time.
SC 13G/A - PepGen Inc. (0001835597) (Subject)
SC 13G - PepGen Inc. (0001835597) (Subject)
SC 13G/A - PepGen Inc. (0001835597) (Subject)
SC 13G - PepGen Inc. (0001835597) (Subject)
SC 13G - PepGen Inc. (0001835597) (Subject)
SC 13D/A - PepGen Inc. (0001835597) (Subject)
SC 13G/A - PepGen Inc. (0001835597) (Subject)
SC 13D/A - PepGen Inc. (0001835597) (Subject)
SC 13G/A - PepGen Inc. (0001835597) (Subject)
SC 13G/A - PepGen Inc. (0001835597) (Subject)